Value in Health Regional Issues

Slides:

Advertisements

Similar presentations

Value in Health Regional Issues

Advertisements

Volume 16, Issue 6, Pages (September 2013)

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Value in Health Regional Issues

Epidemiology of Malaria in Latin America and the Caribbean from 1990 to 2009: Systematic Review and Meta-Analysis Ariel Bardach, MD, MSc, PhD, Agustín.

The Development of the Romanian Scorecard HTA System

Volume 147, Issue 1, Pages (July 2014)

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Value in Health Regional Issues

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Hepatitis B and C virus-related carcinogenesis

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan Kaoru Yamabe, MSc, Puneet K. Singhal,

Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making

Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil Ronaldo K.

Value in Health Regional Issues

Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F

Ernest Attuquaye Quaye, BPharm, MPH, Edward O

Value in Health Regional Issues

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Klára Kruntorádová, MSc, Jiří Klimeš,

Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea Bo-Ra-Mi Kim, MPH, Tae-Jin Lee, PhD,

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

Value in Health Regional Issues

Value in Health Regional Issues

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,

What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.

Hepatitis C Virus Infection in the Older Patient

Assessment of Adverse Events and Quality of Life of Cancer Patients in a Secondary Level Care, Rural Hospital in South India S.K.R. Sowmya, PharmD, Dixon.

Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire Bhavik Shah,

Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Omneya Mohamed, PhD, David H. Kreling, PhD

Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.

Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M

Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan

Value in Health Regional Issues

A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project Kyriakos Souliotis, PhD,

Hepatitis B and C virus-related carcinogenesis

Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,

Value in Health Regional Issues

Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters? Chun-Ru Chien, MD, PhD, Ya-Chen Tina.

Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia Juan-Carlos Castro, MD,

Incidence of Intravenous Medication Errors in a Chinese Hospital

Volume 138, Issue 2, Pages e6 (February 2010)

Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan Yoshie Onishi, MS,

Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers Valentina.

Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD

Guidance Document: Global Pharmacoeconomic Model Adaption Strategies

Value in Health Regional Issues

Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome Allison J. Kasmari, MD, Amy Welch, MD, MSN,

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.

Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences Zobair M. Younossi, Aybike Birerdinc,

Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico

Social Cost of Substance Abuse in Russia

Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD

Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.

A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina Joaquín.

Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.

Value in Health Regional Issues

Economic Impact of Venous Thromboembolism Following Major Orthopaedic Surgery in Japan Shinro Takai, MD, PhD, Masao Akagi, MD, PhD, Bruce Crawford, MA,

Economic Burden of Incident Unplanned Starts on Peritoneal Dialysis in a High Specialty Health Care Facility in Mexico City Sergio O. Hdez Ordonez, MD,

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Value in Health Regional Issues Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection Philip McEwan, PhD, Thomas Ward, MSc, Chien-Jen Chen, PhD, Mei-Hsuan Lee, PhD, Hwai-I Yang, PhD, Ray Kim, MD, Gilbert L’Italien, PhD, Yong Yuan, PhD Value in Health Regional Issues Volume 3, Pages 5-11 (May 2014) DOI: 10.1016/j.vhri.2013.08.001 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Incident cases of confirmed HCC in Taiwan with estimated HCV-related HCC. HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: (10.1016/j.vhri.2013.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Flow diagram of the MONARCH model. Annual transition probabilities control progression through disease states. HCC, hepatocellular carcinoma; HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: (10.1016/j.vhri.2013.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Estimated cumulative number of chronic hepatitis C infections with bootstrapped 95% confidence intervals. HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: (10.1016/j.vhri.2013.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Cumulative estimated prevalence of chronic HCV by fibrosis stage. As of 2012, it is estimated that 23.0%, 19.0%, 14.6%, 22.3%, and 21.1% of the 555,313 patients with chronic HCV are in fibrosis sages F1, F2, F3, and F4, respectively. Value in Health Regional Issues 2014 3, 5-11DOI: (10.1016/j.vhri.2013.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Estimated prevalence of chronic HCV with varying ‘minimum incidence caps.’ HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: (10.1016/j.vhri.2013.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 6 (A) Estimated prevalence of hepatocellular carcinoma and chronic HCV per year. (B) Estimated incidence of liver transplants and liver-related deaths per year. HCC, hepatocellular carcinoma; HCV, hepatitis C virus. Value in Health Regional Issues 2014 3, 5-11DOI: (10.1016/j.vhri.2013.08.001) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions